SCHEMBL1094871

SCHEMBL1094871

O=S(=O)(Nc1nccs1)c1cccc(F)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
LMNA P02545 2/20 0.57
KDM4E B2RXH2 1/20 0.57
CYP2C9 P11712 1/20 0.57
EDNRA P25101 1/20 0.57
SLC6A4 P31645 1/20 0.57
ADRA1A P35348 1/20 0.57
PRMT6 Q96LA8 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
SCN9A Q15858 8/20 0.57
PKM P14618 3/20 0.56
SCN3A Q9NY46 1/20 0.53
CYP1A2 P05177 1/20 0.52
ATM Q13315 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13230136 0.83 PKM (0.60) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL1576750 0.83 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL19613863 0.83 LMNA (0.69) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL9301181 0.83 ALDH1A1 (0.69) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL326633 0.82 ALDH1A1 (0.71) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL1093893 0.81 LMNA (0.67) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL15651969 0.81 ALDH1A1 (0.55) ALDH1A1MEN1KMT2ALMNAKDM4E
Hydrochloric Acid SCHEMBL27575105 0.80 ALDH1A1 (0.69) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL1093571 0.80 GLO1 (0.56) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL9301664 0.79 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
WO-2014170793-A1 SULFONAMIDES FOR THE TREATMENT OF GOUT PFIZER LIMITED (GB) 2014-10-23 WO disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 ALDH1A1 1369/4885MEN1 4141/4885KMT2A 3314/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 ALDH1A1 1369/4885MEN1 4141/4885KMT2A 3314/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 ALDH1A1 1369/4885MEN1 4141/4885KMT2A 3314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.